Navigation Links
Signum Dermalogix Receives $1.6M Phase II SBIR Grant for the Development of Novel Atopic Dermatitis Therapeutics
Date:11/14/2013

PRINCETON, N.J., Nov. 14, 2013 /PRNewswire/ -- Signum Dermalogix, Inc. ("Dermalogix") announced today that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the company a Small Business Innovation Research (SBIR) Phase II grant totaling $1.6 million for the development of a topical drug candidate for atopic dermatitis.  

Utilizing the funding provided with the earlier Phase I grant, Dermalogix established a novel screening paradigm to effectively identify potent therapeutic compounds from its isoprenylcysteine (IPC) technology platform. These screening efforts resulted in the identification of several IPC compounds possessing anti-inflammatory and anti-microbial activity. This Phase II funding will be used to select a lead drug candidate and commence IND-enabling safety/toxicology studies.

"This award is further validation of the potential for IPC compounds in dermatology. We are pleased to be awarded this grant by the NIH and our objective continues to be the development of our technology with the goal of delivering therapeutic agents to treat skin disease," stated Maxwell Stock, President & CEO.

Dermalogix has a successful track record in receiving and executing on NIH funding. Recently, with National Institute of Allergy and Infectious Diseases (NIAID) SBIR funding, Dermalogix announced that an Investigational New Drug (IND) Application to evaluate IPC compound SIG990 in rosacea has been cleared by the FDA. Dr. Eduardo Perez, VP of R&D and Business Development stated, "Building on the experience and momentum provided by SIG990, we believe successful development of our novel class of topical IPC compounds will provide an important additional, and potentially better, therapeutic option for people suffering atopic dermatitis."  

About Signum Dermalogix
Signum Dermalogix is a dermatological focused company, developing novel cosmetic ingredients and drug compounds. Dermalogix also provides dermatology testing, custom assay development and analytical services. For more information please visit: www.signumdermalogix.com


'/>"/>
SOURCE Signum Dermalogix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
2. IntelligentMDx Receives FDA Clearance for IMDx C. difficile for Abbott m2000 Assay, Completes Move of Corporate Headquarters to Waltham
3. Numotion Receives 2013 MDA Company of the Year Award
4. EndoShape Receives 510(k) Clearance for Polymer Embolization Device
5. Actinobac Biomed Founder Receives Two Awards For Promising New Drug
6. ARMGO Pharma Receives Research Grant Award from Kennedys Disease Association to Support Advancement of Rycal Compounds
7. Seventh Sense Biosystems Receives CE Mark Approval for its Touch Activated Phlebotomy Blood Collection and Testing System
8. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
9. ARRAYit Corporation Receives Purchase Order from ChemBio
10. IGI Laboratories, Inc. Receives Formal US FDA Approval For Site Transfer Of Econazole Nitrate
11. Par Pharmaceuticals Karen OConnor Receives 2013 Cardinal Health Supply Chain Excellence Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , Jan. 23, 2017  HOPE BIOSCIENCES announced ... to develop and commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) ... Korean pharmaceutical company. nuc -Gemcitabine ... against surface nucleolin found on many cancer cells, ... ADCs (antibody drug conjugates) or SMDCs (small molecule ...
(Date:1/23/2017)... ROCKVILLE, Md. , Jan. 23, 2017 /PRNewswire/ ... to advancing a new standard in respiratory care, ... Committee for Orphan Medicinal Products has granted Orphan ... the treatment of Bronchiolitis Obliterans Syndrome (BOS).  ... Drug Designation from the EMA to treat patients ...
(Date:1/23/2017)... Jan. 23, 2017  Based on its recent ... Sullivan recognizes Ansell, a global leader in protection ... Company of the Year Award. Ansell,s comprehensive product ... wide global footprint have placed it in a ... market. The Company,s established product line and robust ...
Breaking Medicine Technology:
(Date:1/24/2017)... , ... January 24, 2017 , ... ... visualize, detect, and eliminate cyber threats in real-time, today announced a strategic partnership ... will enable customers to monitor, respond and protect their critical information assets and ...
(Date:1/24/2017)... ... ... His message has been heard by more than 100,000 students and adults across ... Feldman, has reached his biggest national audience yet: the three million daily readers of ... circulation in the country, and he hopes it will help spread his message and ...
(Date:1/24/2017)... ... January 24, 2017 , ... This Saturday, January 28, the BCFA ... very special performance by Alabama Symphony Orchestra musicians Yifan Zhou, Mara McClain & Sarah ... dim sum, and exhibitors offer a look at Chinese games, crafts & more. Festivities ...
(Date:1/24/2017)... Boston, MA (PRWEB) , ... January 24, 2017 ... ... What They Really Need to Thrive , Well-meaning studies such as the Fordham ... and schools can better serve top students, such as including gifted or high-achieving ...
(Date:1/24/2017)... ... January 24, 2017 , ... Date aired: ... , Sharon Kleyne, the nation’s foremost water advocate and host of the nationally ... Health on Voice America, once again welcomed one of her favorite guests and ...
Breaking Medicine News(10 mins):